Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

The Von Willebrand Disease Treatment Market will register a CAGR of almost 7% by 2023
By: PR Newswire Association LLC. - 11 Dec 2018Back to overview list

LONDON, Dec. 10, 2018 /PRNewswire/ --

About this market
The increasing awareness about VWD is likely to boost growth in the market. VWD will be present in the affected individual since the time of birth; however, the symptoms do not appear from childhood. Patients' perceptions of symptoms such as frequent nosebleeds, staining and extreme bleeding during and after invasive events such as dental extractions and surgical procedures are general changing gradually. Technavio's analysts have predicted that the von Willebrand disease treatment market will register a CAGR of almost 7% by 2023.



Download the full report: https://www.reportbuyer.com/product/5647268



Market Overview
Rising number of assistance programs for patients
The rising number of assistance programs for patients who need treatment of von Willebrand disease is pushing growth in the von Willebrand disease treatment market.
Cost intensive treatment
High cost of treatment is one of the major challenges for patients with VWD. As VWD is one of the very rare blood diseases, the patient pool available for carrying out clinical trials is negligible, which increases the research cost.
For the detailed list of factors that will drive and challenge the growth of the von Willebrand disease treatment market during the 2019-2023, view our report.

Competitive Landscape
The market appears to be highly concentrated and with the presence of few companies including Baxter and CSL the competitive environment is quite intense. Factors such as the increasing awareness about VWD and the rising number of assistance programs for patients, will provide considerable growth opportunities to von Willebrand disease treatment manufactures. Baxter, CSL, Octapharma, Shire, and Grifols are some of the major companies covered in this report.

'With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.'

Download the full report: https://www.reportbuyer.com/product/5647268

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

 

Cision View original content:http://www.prnewswire.com/news-releases/the-von-willebrand-disease-treatment-market-will-register-a-cagr-of-almost-7-by-2023-300762811.html

SOURCE ReportBuyer

Copyright 2018 PR Newswire Association LLC. Back to overview list
to the top ↑